Clinical Impact of Initiating Insulin Glargine Therapy with Disposable Pen Versus Vial in Patients with Type 2 Diabetes Mellitus in a Managed Care Setting
- 1 November 2011
- journal article
- research article
- Published by Elsevier BV in Endocrine Practice
- Vol. 17 (6), 845-852
- https://doi.org/10.4158/ep10401.or
Abstract
No abstract availableThis publication has 23 references indexed in Scilit:
- Dosing accuracy of commonly used disposable insulin pensCurrent Medical Research and Opinion, 2010
- Barriers to Insulin InitiationDiabetes Care, 2010
- Standards of Medical Care in Diabetes—2010Diabetes Care, 2010
- Projecting the Future Diabetes Population Size and Related Costs for the U.S.Diabetes Care, 2009
- Persistence with injectable antidiabetic agents in members with type 2 diabetes in a commercial managed care organizationCurrent Medical Research and Opinion, 2009
- Pen Devices to Improve Patient Adherence With Insulin Therapy in Type 2 DiabetesPostgraduate Medicine, 2008
- Comparison of usability and patient preference for the new disposable insulin device solostar versus flexpen, lilly disposable pen, and a prototype pen: an open-label studyClinical Therapeutics, 2007
- Health Care Costs and Medication Adherence Associated with Initiation of Insulin Pen Therapy in Medicaid-Enrolled Patients with Type 2 Diabetes: A Retrospective Database AnalysisClinical Therapeutics, 2007
- Preference for insulin delivery systems among current insulin users and nonusersClinical Therapeutics, 2004
- The central role of the propensity score in observational studies for causal effectsBiometrika, 1983